Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive Disorder

• Conditions: Major Depressive Disorder; MedDRA version: 16.0Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873; MedDRA version: 16.0Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2011-005179-18-EE
• Lead Sponsor: Forest Research Institute, Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12-29
• Last Update Posted: 17 February 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 810

Inclusion Criteria

To be eligible to participate in the study, patients must meet the
following criteria:
1. Written informed consent, signed or thumbprinted (only if allowed by
local
regulations), obtained from the patient before the initiation of any
study-specific
procedures
2. Male or female outpatients 18 to 65 years of age, inclusive
3. Currently meet the DSM-IV-TR criteria for MDD without psychotic
features based
on the Structured Clinical Interview for Diagnostic Statistic Manual of
Mental Health
Disorders, Fourth Edition (SCID), with a current major depressive
episode of at least
8 weeks and not exceeding 24 months in duration at Visit 1
4. Ongoing inadequate response to protocol allowed ADT (bupropion,
citalopram,
desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline,
venlafaxine, or
vilazodone) administered at adequate dose and duration in accordance
XML File Identifier: EyBIDO9jDoz4RpZr1nNSEG1ScS4=
Page 23/38
with the
respective package insert, documented in the Antidepressant Treatment
History Form
(ATHF) with a resistance rating of = 3 and a global confidence score of =
3
5. Montgomery-Asberg Depression Rating Scale (MADRS) total score =
22 at both
Screening (Visit 1) and Baseline (Visit 2)
6. Normal physical examination findings, clinical laboratory results, and
electrocardiogram (ECG) results from Screening (Visit 1) or abnormal
findings
judged not clinically significant by the PI and documented as such in the
eCRF
7. Body mass index between 18 and 40, inclusive
8. If female of child bearing potential, have a negative serum ß-human
chorionic
gonadotropin (ß-hCG]) pregnancy test
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 810
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Psychiatric Criteria:
1. Principal DSM-IV-TR–based diagnosis of an axis I disorder, other than
MDD, or
any axis I disorder other than MDD that was the primary focus of
treatment within
6 months before Visit 1 (secondary diagnoses of comorbid generalized
anxiety
disorder, social anxiety disorder, or specific phobias are acceptable)
2. History of meeting DSM-IV-TR criteria for:
a. Any depressive episode with psychotic or catatonic features
b. Any manic, hypomanic or mixed episode, including bipolar disorder
and
substance-induced (eg, antidepressant-induced) manic, hypomanic or
mixed
episode
c. Schizophrenia, schizoaffective, or other psychotic disorder
d. Panic disorder, with or without agoraphobia
e. Obsessive-Compulsive disorder
f. Bulimia or Anorexia Nervosa
g. Dementia, amnesic, or other cognitive disorder
h. Mental retardation
3. Meeting full DSM-IV-TR criteria for MDD with seasonal pattern AND
the
patient's season of remission would occur during the study.
4. DSM-IV-TR–based diagnosis of borderline or antisocial personality
disorder or other
axis II disorder of sufficient severity to interfere with participation in
this study
5. History of meeting DSM-IV-TR criteria for alcohol or substance abuse
or dependence
(other than nicotine or caffeine) within the 6 months before Visit 1
6. Positive result on blood alcohol test or for any prohibited medication
on the urine
drug screen with the following stipulations:
? Patients with a positive urine drug screen for cannabinoids,
barbiturates, opiates,
amphetamines, or benzodiazepines may be allowed in the study provided
that the
drug was used for a legitimate medical purpose and the use of such
products can
XML File Identifier: EyBIDO9jDoz4RpZr1nNSEG1ScS4=
Page 24/38
be discontinued (documented by a negative repeat test) before
participation
beyond screening
? Medically appropriate episodic use (up to 3 days) of narcotic analgesics
for acute
medical indications is allowed
? Discussion with Medical Monitor is recommended in any potential
exception
listed above
? Positive results for methadone, phencyclidine, and cocaine are
exclusionary with
no exceptions
7. Suicide risk, as determined by meeting any of the following criteria:
? A suicide attempt within the past year
? Significant risk, as judged by the PI, based on the psychiatric interview
or
information collected in the Columbia–Suicide Severity Rating Scale (CSSRS)
at
Visit 1 or Visit 2
? MADRS Item 10 score = 5 at Visit 1 or Visit 2
8. At imminent risk of injuring self or others or causing significant
damage to property,
as judged by the PI
9. Requires hospitalization
Treatment-Related Criteria:
10. Treatment refractory depression as defined by:
? Failure to respond (< 50% reduction in depressive symptoms) to = 3
ADTs
given at adequate dose (as defined by the ADT package insert) and
duration of
> 6 weeks during the present episode
? History of inadequate response to ECT, a monoamine oxidase inhibitor,
or
adjunctive treatment with an antipsychotic
11. Having a history of treatment with clozapine or any depot
antipsychotic (exception:
episodic use of clozapine at doses = 150 mg/day for the treatment of
insomnia)
12. Having received any antipsychotic, anticonvulsant/mood stabilizer,
anxiolytic,
benzodiazepine, or other ADT augmentation agent (eg, T3 [except as
treatment for
thyroid condition], 2nd antidepressant, etc.) within 1 week or 5 half lives
of the

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified